Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

PROCEPT BioRobotics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

PROCEPT BioRobotics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$2.01
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PRCT in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PRCT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

PROCEPT BioRobotics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PRCT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PRCT)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (PRCT)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PRCT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PRCT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PRCT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PRCT keine Ausschüttungen gemeldet hat.

PROCEPT BioRobotics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock

Executive VP & CFO recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

No longer forecast to breakeven

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

PROCEPT BioRobotics Corporation to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

PROCEPT BioRobotics Corporation Projects Earnings Guidance for the Full Year 2022

Now 20% undervalued

PROCEPT BioRobotics Corporation to Report Q3, 2022 Results on Nov 03, 2022

Procept Biorobotics announces $52M debt refinancing

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Procept BioRobotics Has Resources To Ramp Up Commercialization

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.43 loss per share (vs US$2.61 loss in 2Q 2021)

PROCEPT BioRobotics Corporation to Report Q2, 2022 Results on Aug 04, 2022

PROCEPT BioRobotics Corporation(NasdaqGM:PRCT) dropped from Russell 2500 Value Index

Independent Director exercised options and sold US$663k worth of stock

BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

PROCEPT BioRobotics Corporation to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

PROCEPT BioRobotics Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target